GlassScriptPhysician profile
Serafim Perdikis
NPI 1780786822
$5,204.70
in general payments reported to CMS, 2019-2025
14 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $41.04 · 2021: $652 · 2022: $354 · 2023: $2,378 · 2024: $730 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883 · Travel and Lodging: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.28 |
| Travel and Lodging | $1,494.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,554.34 | 2019-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $693.23 | 2019-2025 | Impella |
| Pfizer INC. | $347.56 | 2019 | |
| Medtronic, INC. | $303.65 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $254.26 | 2020-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $236.82 | 2025 | Camzyos |
| Lantheus Medical Imaging, INC. | $195.18 | 2022-2023 | Definity |
| Janssen Pharmaceuticals, INC | $153.41 | 2022 | |
| Cvrx, INC. | $131.18 | 2023 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $128.19 | 2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $116.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.85 | 2023-2024 | Farxiga, Wainua |
| Kiniksa Pharmaceuticals International, Plc | $25.04 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $15.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serafim Perdikis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.